FDA grants priority review to liso cel for treatment of adult patients with relapsed or refractory large B-cell lymphoma.- BMS
Related news and insights
Genentech, a member of the Roche Group announced results from the Phase III POLARIX study showing that treatment with Polivy (polatuzumab vedotin) in combination with Rituxan (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) significantly reduced the risk of disease progression, relapse or death (progression-free survival; PFS) by 27% compared with the current standard-of-care, Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), in people with previously untreated diffuse large B-cell lymphoma (DLBCL).
Bristol Myers Squibb announced the first disclosure of results from a prespecified interim analysis of the pivotal TRANSFORM study, a global, randomized, multicenter, Phase III study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, as a second-line treatment in adults with relapsed or refractory large B-cell lymphoma (LBCL) compared to the standard of care consisting of salvage chemotherapy followed by high-dose chemotherapy plus autologous hematopoietic stem cell transplant (HSCT).
MorphoSys announced additional real-world evidence results from the RE-MIND2 study comparing Monjuvi (tafasitamab) in combination with Revlimid (lenalidomide) against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).